{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:23:11Z","timestamp":1792664591985,"version":"4.5.0"},"reference-count":31,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:00:00Z","timestamp":1713484800000},"content-version":"unspecified","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2024,4,8]]},"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:p>Classification criteria have been developed for rheumatoid arthritis (RA) and other rheumatic diseases in order to gather a homogeneous patient population for clinical studies and facilitate the timely implementation of therapeutic measures. Although classification criteria are not intended to be used for diagnosis, they are frequently used to support the diagnostic process in clinical practice, including clinical decision-making. The 2010 American College of Rheumatology (ACR)\/European Alliance of Associations for Rheumatology (EULAR) classification criteria for RA are capable of identifying the majority of symptomatic patients with RA already in the earliest stages of the disease who are not yet showing radiographic changes. These patients will also profit from the early implementation of therapy with disease-modifying antirheumatic drugs (DMARDs). However, the risk of misclassification is higher as compared with the former 1987 ACR criteria, which were considerably less sensitive to the recognition of patients with early RA. Of note, the presence of rheumatoid factors (RFs) and anticitrullinated protein antibodies (ACPAs) has been attributed equal weight in the 2010 ACR\/EULAR criteria and may contribute up to 50% of the score needed for being classified as RA. However, while ACPAs have been proven to be the most specific serological markers of RA, the specificity of RF is moderate, especially at lower titres. This may lead to the misclassification of RF-positive patients and, consequently, the unjustified implementation of DMARD therapy. Therefore, issues arise on how comprehensive the criteria should be and whether they should be updated and adapted to findings from the past two decades that might increase both their specificity and sensitivity.<\/jats:p>","DOI":"10.1136\/rmdopen-2023-003851","type":"journal-article","created":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T03:45:22Z","timestamp":1713584722000},"page":"e003851","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":14,"title":["Classification of rheumatoid arthritis: is it time to revise the criteria?"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5089-7405","authenticated-orcid":false,"given":"Guenter","family":"Steiner","sequence":"first","affiliation":[{"name":"Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Wien, Wien, Austria"},{"name":"Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Wien, Wien, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0340-3580","authenticated-orcid":false,"given":"Patrick","family":"Verschueren","sequence":"additional","affiliation":[{"name":"Rheumatology, KU Leuven University Hospitals Leuven, Leuven, Belgium"},{"name":"Skeletal Biology and Engineering Research Centre, Department of Development and Regeneration, KU Leuven Biomedical Sciences Group, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3462-7288","authenticated-orcid":false,"given":"Lieve","family":"Van Hoovels","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium"},{"name":"Department of Laboratory Medicine, OLV Ziekenhuis, Aalst, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8895-6941","authenticated-orcid":false,"given":"Paul","family":"Studenic","sequence":"additional","affiliation":[{"name":"Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Wien, Wien, Austria"},{"name":"Department of Medicine (Solna), Division of Rheumatology, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6856-8485","authenticated-orcid":false,"given":"Xavier","family":"Bossuyt","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium"},{"name":"Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,4,19]]},"reference":[{"key":"2025090312265440000_10.2.e003851.1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2018.1"},{"key":"2025090312265440000_10.2.e003851.2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.13103"},{"key":"2025090312265440000_10.2.e003851.3","unstructured":"Baker JF . Diagnosis and differential diagnosis of RA. UpToDate; 2024. Available: www.update.com\/content"},{"key":"2025090312265440000_10.2.e003851.4","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24596"},{"key":"2025090312265440000_10.2.e003851.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220973"},{"key":"2025090312265440000_10.2.e003851.6","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/acr.22583","article-title":"Distinctions between diagnostic and classification criteria","volume":"67","author":"Aggarwal","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312265440000_10.2.e003851.7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2022.100144","article-title":"Autoantibodies in the criteria of autoimmune diseases:is it sufficient to know that the test is positive","volume":"5","author":"Damoiseaux","year":"2022","journal-title":"J Transl Autoimmun"},{"key":"2025090312265440000_10.2.e003851.8","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.138461"},{"key":"2025090312265440000_10.2.e003851.9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2022.100142","article-title":"Impact of autoimmune serology test results on RA classification and diagnosis","volume":"5","author":"Van Hoovels","year":"2022","journal-title":"J Transl Autoimmun"},{"key":"2025090312265440000_10.2.e003851.10","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302"},{"key":"2025090312265440000_10.2.e003851.11","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-002099","article-title":"A multicenter study to improve clinical interpretation of rheumatoid factor and anti-citrullinated protein\/peptide antibodies test results","volume":"8","author":"Van Hoovels","year":"2022","journal-title":"RMD Open"},{"key":"2025090312265440000_10.2.e003851.12","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/art.40562","article-title":"Triple positivity for anti-citrullinated protein autoantibodies, rheumatoid factor, and anti-carbamylated protein antibodies conferring high specificity for rheumatoid arthritis: implications for very early identification of at-risk individuals","volume":"70","author":"Verheul","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2025090312265440000_10.2.e003851.13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00876","article-title":"Determination of autoantibody isotypes increases the sensitivity of serodiagnostics in rheumatoid arthritis","volume":"9","author":"Sieghart","year":"2018","journal-title":"Front Immunol"},{"key":"2025090312265440000_10.2.e003851.14","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1515\/cclm-2022-0244","article-title":"IgA rheumatoid factor in rheumatoid arthritis","volume":"60","author":"Van Hoovels","year":"2022","journal-title":"Clin Chem Lab Med"},{"key":"2025090312265440000_10.2.e003851.15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202127"},{"key":"2025090312265440000_10.2.e003851.16","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1093\/rheumatology\/kex340","article-title":"The risk of individual autoantibodies, autoantibody combinations and levels for arthritis development in clinically suspect arthralgia","volume":"56","author":"ten Brinck","year":"2017","journal-title":"Rheumatology"},{"key":"2025090312265440000_10.2.e003851.17","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.clinthera.2019.04.017","article-title":"Predicting rheumatoid arthritis in at-risk individuals","volume":"41","author":"van Boheemen","year":"2019","journal-title":"Clin Ther"},{"key":"2025090312265440000_10.2.e003851.18","doi-asserted-by":"publisher","DOI":"10.1002\/art.30100"},{"key":"2025090312265440000_10.2.e003851.19","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.143560"},{"key":"2025090312265440000_10.2.e003851.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201909"},{"key":"2025090312265440000_10.2.e003851.21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203284"},{"key":"2025090312265440000_10.2.e003851.22","doi-asserted-by":"crossref","first-page":"103421","DOI":"10.1016\/j.autrev.2023.103421","article-title":"Should ACR\/EULAR criteria be revised changing the RF and ACPA scores","volume":"23","author":"Steiner","year":"2024","journal-title":"Autoimmun Rev"},{"key":"2025090312265440000_10.2.e003851.23","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.122473"},{"key":"2025090312265440000_10.2.e003851.24","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1093\/rheumatology\/keab880","article-title":"Undifferentiated arthritis: a changing population who did not benefit from enhanced disease-modifying anti-rheumatic drug strategies-results from a 25 year longitudinal inception cohort","volume":"61","author":"Verstappen","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2025090312265440000_10.2.e003851.25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220884"},{"key":"2025090312265440000_10.2.e003851.26","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/s41584-023-01035-y","article-title":"RA prevention in arthralgia: fantasy or reality?","volume":"19","author":"Van Steenbergen","year":"2023","journal-title":"Nat Rev Rheum"},{"key":"2025090312265440000_10.2.e003851.27","first-page":"554","article-title":"Seronegative rheumatoid arthritis: one year in review 2023","volume":"41","author":"De Stefano","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312265440000_10.2.e003851.28","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-020-02191-2","article-title":"Presence of autoantibodies in \u2018seronegative\u2019 rheumatoid arthritis associates with classical risk factors and high disease activity","volume":"22","author":"Reed","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2025090312265440000_10.2.e003851.29","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-015-0860-6","article-title":"The specificity of anti-carbamylated protein antibodies for rheumatoid arthritis in a setting of early arthritis","volume":"17","author":"Shi","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2025090312265440000_10.2.e003851.30","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211022533","article-title":"Presence of anti-acetylated peptide antibodies (AAPA) in inflammatory arthritis and other rheumatic diseases suggests Discriminative diagnostic capacity towards early rheumatoid arthritis","volume":"13","author":"Studenic","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2025090312265440000_10.2.e003851.31","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-73919-y","article-title":"Improved classification of rheumatoid arthritis with a score including anti-acetylated ornithine antibodies","volume":"10","author":"Rodriguez-Mart\u00ednez","year":"2020","journal-title":"Sci Rep"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2023-003851","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:27:05Z","timestamp":1756927625000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2023-003851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,4,19]]},"published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1136\/rmdopen-2023-003851"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2023-003851","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]}}}